Immutep CSO and CMO, Dr Frederic Triebel said: “We are pleased...

Immutep CSO and CMO, Dr Frederic Triebel said: “We are pleased with the recruitment of patients in theTACTI-002 clinical trial to date. After dosing the first patient in March this year, we already have 32 patientson study. In addition, we are encouraged by the early signals of efficacy seen in the more advanced part A ofthe study that appear to be consistent with the synergistic efficacy seen in combining efti withpembrolizumab in the TACTI-mel clinical trial. We very much look forward to presenting more detailed andmore mature data at the 34th Annual Meeting of SITC in November.”

We should get a good little rally here so far so good.....